AAA

ALZECURE PHARMA AB

No trades
See on Supercharts
Market capitalization
‪124.17 M‬SEK
−0.600SEK
‪−37.17 M‬SEK
‪44.55 M‬
Beta (1Y)
−0.72

About ALZECURE PHARMA AB

CEO
Martin Jönsson
Headquarters
Huddinge
Employees (FY)
11
Founded
2016
ISIN
SE0010133785
FIGI
BBG00M6GTHQ2
AlzeCure Pharma AB is a pharmaceutical research company. It engages in the development of drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The firm is developing parallel drug candidates based on the research platforms, such as NeuroRestore, Alzstatin, and Painless. The company was founded by Johan Sandin, Gunnar Nordvall, Pontus Forsell, Johan Lundkvist, and Magnus Halldin on November 22, 2016 and is headquartered in Huddinge, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ALZCUR is 2.030 SEK — it has increased by 1.50% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange ALZECURE PHARMA AB stocks are traded under the ticker ALZCUR.
ALZECURE PHARMA AB is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
ALZCUR stock is 12.47% volatile and has beta coefficient of −0.72. Check out the list of the most volatile stocks — is ALZECURE PHARMA AB there?
Yes, you can track ALZECURE PHARMA AB financials in yearly and quarterly reports right on TradingView.
ALZCUR stock has risen by 1.00% compared to the previous week, the month change is a 34.73% fall, over the last year ALZECURE PHARMA AB has showed a 56.62% decrease.
ALZCUR net income for the last quarter is ‪−9.76 M‬ SEK, while the quarter before that showed ‪−7.66 M‬ SEK of net income which accounts for −27.45% change. Track more ALZECURE PHARMA AB financial stats to get the full picture.
Today ALZECURE PHARMA AB has the market capitalization of ‪124.17 M‬, it has increased by 22.58% over the last week.
No, ALZCUR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ALZCUR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALZECURE PHARMA AB stock right from TradingView charts — choose your broker and connect to your account.
ALZCUR reached its all-time high on Nov 4, 2020 with the price of 11.625 SEK, and its all-time low was 1.595 SEK and was reached on Apr 2, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 20, 2024, the company has 11.00 employees. See our rating of the largest employees — is ALZECURE PHARMA AB on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ALZECURE PHARMA AB technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ALZECURE PHARMA AB stock shows the sell signal. See more of ALZECURE PHARMA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.